Serina Therapeutics Announces Completion of Cohort 1 Enrollment, Dosing in SER-252 Parkinson’s Trial
SERA•Cohort 1 enrollment and dosing completed
Serina Therapeutics disclosed completion of Cohort 1 enrollment and dosing in its Phase 1b registrational trial of SER-252.
Eight advanced Parkinson’s patients were dosed across U.S. and Australian sites, ahead of prior guidance for end-Q3 2026 completion.
Next safety review will guide dose escalation
An independent Safety Monitoring Committee will review blinded Cohort 1 safety and tolerability to guide the next dose-escalation step.
